Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study
Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Design

Study Design: SINGLE

- **Background**: Randomized, double-blind study, phase 3 trial comparing dolutegravir + abacavir-lamivudine with efavirenz-tenofovir DF-emtricitabine

- **Inclusion Criteria (n = 833)**
  - Antiretroviral-naïve adults
  - Age ≥18
  - HIV RNA ≥1,000 copies/mL
  - No active CDC AIDS condition

- **Treatment Arms**
  - Dolutegravir (QD) + Abacavir-lamivudine
  - Efavirenz-Tenofovir DF-Emtricitabine

---

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Result

Week 48 Virologic Response (ITT Analysis)

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Result

Week 48 Virologic Response (ITT Analysis)

Discontinuation of therapy due to adverse events
Dolutegravir + Abacavir-Lamivudine: 2%
Efavirenz-Tenofovir-Emtricitabine: 10%

HIV RNA <50 copies/mL (%)

Baseline HIV RNA

All ≤100,000 copies/mL >100,000 copies/mL

Dolutegravir + Abacavir-Lamivudine 88 81 90 83
Efavirenz-Tenofovir DF-Emtricitabine 83 83 76

Baseline HIV RNA

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Result

Mean Change from Baseline in Serum Creatinine Levels

© 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
**Conclusions**: “Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*